Consequences of chronic hepatitis C: a review article for the hematologist.

Abstract

The hepatitis C virus (HCV) has been cloned, and assays capable of detecting antibody to HCV recombinant proteins (anti-HCV) have been developed. Concurrent with the cloning and development of the anti-HCV screening tests, trials with interferon alfa-2b have documented biochemical and histologic improvement in the indices of hepatitis C and non-A, non-B (NANB) in patients who were chronically infected. Subsequently, the anti-HCV assays and interferon alfa-2b have become clinically available. These new detection and treatment modalities can now be used in the management of hemophilics and other chronically transfused patients who bear great risk for blood-borne infections and manifest signs of chronic hepatitis.

• Authors: L M Aledort
• Journal: American journal of hematology (Am J Hematol) Vol. 44 Issue 1 Pg. 29-37 (Sep 1993) ISSN: 0361-8609 [Print] United States
• PMID: 8342562 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)

Topics

• Chronic Disease
• Hematology
• Hepatitis C (complications, diagnosis, therapy)
• Humans